StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CTEV yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $19.00 | $13.87 | -27.00% | 0.7M |
| 05-18 | $12.91 | $16.42 | +27.19% | 1.1M |
| 05-19 | $16.01 | $16.20 | +1.19% | 0.2M |
| 05-20 | $18.07 | $21.24 | +17.54% | 0.4M |
| 05-21 | $20.93 | $23.09 | +10.32% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $244.68M | $965.41M | $718.86M | $472.90M |
Operating Income | $6.64M | $28.77M | $36.39M | $26.32M |
Net Income | $-73.56M | $-284.28M | $-203.71M | $-133.96M |
EPS (Diluted) | $-4.41 | $-17.30 | $-12.42 | $-8.19 |
Total Assets | $4.84B | $4.89B | $4.99B | $5.07B |
Total Liabilities | $5.07B | $5.06B | $5.09B | $5.11B |
Cash & Equivalents | $21.33M | $16.81M | $39.15M | $56.39M |
Free Cash Flow OCF − CapEx | $-92.55M | $-12.28M | $-48.65M | $-32.31M |
Shares Outstanding | 17.00M | 16.55M | 16.51M | 16.47M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.